Qrons is a biotechnology company dedicated to developing biotech products, treatments and technologies that create a platform to combat neuronal diseases. Its approach seeks to marshal and leverage the remarkable advances made in the fields of artificial intelligence (AI), machine learning (ML), molecular biology, stem cells and tissue engineering, for deployment in the fight against neuronal diseases. The company has two product candidates for treating traumatic brain injuries, both integrating proprietary, modified mesenchymal stem cells (MSCs) and smart synthetic material. QS100 is an injury-specific, 3D-printable, implantable MSC-synthetic hydrogel for treating penetrating brain injuries. QS200 is an injectable MSC-synthetic hydrogel for the treatment of concussions. The company conducts its research in Israel under service agreements with Ariel University and has an ongoing sponsored research agreement with Dartmouth College.